Patents by Inventor A. Robert MacLeod

A. Robert MacLeod has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180163209
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a DMPK mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for preferentially reducing CUGexp DMPK RNA, reducing myotonia or reducing spliceopathy in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate type 1 myotonic dystrophy, or a symptom thereof.
    Type: Application
    Filed: July 24, 2017
    Publication date: June 14, 2018
    Applicants: Ionis Pharmaceuticals, Inc., University of Rochester
    Inventors: C. Frank Bennett, Susan M. Freier, Robert A. MacLeod, Sanjay K. Pandey, Charles A. Thornton, Thurman Wheeler, Seng H. Cheng, Andrew Leger, Bruce M. Wentworth
  • Patent number: 9765338
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a DMPK mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for preferentially reducing CUGexp DMPK RNA, reducing myotonia or reducing spliceopathy in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate type 1 myotonic dystrophy, or a symptom thereof.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: September 19, 2017
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Susan M. Freier, Robert A. MacLeod, Sanjay K. Pandey, Charles A. Thornton, Thurman Wheeler, Seng H. Cheng, Andrew Leger, Bruce M. Wentworth
  • Patent number: 9567588
    Abstract: Certain embodiments are directed to compounds and compositions targeted to human androgen receptor (AR) for inhibiting androgen receptor levels in a cell, which can be useful for methods of treating cancer and inhibiting cancer cell growth or proliferation.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: February 14, 2017
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Robert A. Macleod, Youngsoo Kim, Tianyuan Zhou, Susan M. Freier, Punit Seth, Eric Swayze, Brett Monia
  • Patent number: 9546368
    Abstract: The present embodiments provide compounds and methods for reducing expression of Metastasis-Associated-in-Lung-Adenocarcinoma-Transcript-1 (MALAT-1) RNA and/or protein in an animal. Such methods are useful for treating cancer, such as colon cancer, intestinal cancer, lung cancer (e.g. non-small cell lung cancer), liver cancer, and/or prostate cancer. In various aspects, the cancer is a primary cancer.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: January 17, 2017
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Susan M. Freier, Eric G. Marcusson, Ssucheng J. Hsu, Robert A. MacLeod
  • Publication number: 20160348104
    Abstract: Disclosed herein are antisense compounds and methods for decreasing STAT3 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate hyperproliferative diseases.
    Type: Application
    Filed: May 9, 2016
    Publication date: December 1, 2016
    Inventors: Eric E. Swayze, Susan M. Freier, Robert A. MacLeod, Youngsoo Kim
  • Publication number: 20160304877
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a DMPK mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for preferentially reducing CUGexp DMPK RNA, reducing myotonia or reducing spliceopathy in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate type 1 myotonic dystrophy, or a symptom thereof.
    Type: Application
    Filed: August 11, 2014
    Publication date: October 20, 2016
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Eric E. Swayze, Sanjay K. Pandey, Robert A. MacLeod, C. Frank Bennett, Susan M. Freier
  • Patent number: 9359608
    Abstract: Disclosed herein are antisense compounds and methods for decreasing STAT3 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate hyperproliferative diseases.
    Type: Grant
    Filed: July 23, 2014
    Date of Patent: June 7, 2016
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Eric E. Swayze, Susan M. Freier, Robert A. MacLeod, Youngsoo Kim
  • Patent number: 9322021
    Abstract: Disclosed herein are methods for decreasing kallikrein and treating or preventing thromboembolic conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to kallikrein include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Methods for inhibiting kallikrein can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: April 26, 2016
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Alexey Revenko, Gourab Bhattacharjee, Robert A. MacLeod
  • Patent number: 9315811
    Abstract: Disclosed herein are methods for decreasing kallikrein and treating or preventing inflammatory conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to kallikrein include hereditary angioedema (HAE). Methods for inhibiting kallikrein can also be used as a prophylactic treatment to prevent individuals at risk for developing an inflammatory condition, such as, hereditary angioedema.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: April 19, 2016
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Gourab Bhattacharjee, Alexey Revenko, Robert A. MacLeod
  • Publication number: 20160068845
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a DMPK mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for preferentially reducing CUGexp DMPK RNA, reducing myotonia or reducing spliceopathy in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate type 1 myotonic dystrophy, or a symptom thereof.
    Type: Application
    Filed: July 30, 2015
    Publication date: March 10, 2016
    Applicants: UNIVERSITY OF ROCHESTER, ISIS PHARMACEUTICALS, INC.
    Inventors: C. Frank Bennett, Susan M. Freier, Robert A. MacLeod, Sanjay K. Pandey, Charles A. Thornton, Thurman Wheeler, Seng H. Cheng, Andrew Leger, Bruce M. Wentworth
  • Publication number: 20160068846
    Abstract: Certain embodiments are directed to compounds and compositions targeted to human androgen receptor (AR) for inhibiting androgen receptor levels in a cell, which can be useful for methods of treating cancer and inhibiting cancer cell growth or proliferation.
    Type: Application
    Filed: September 15, 2015
    Publication date: March 10, 2016
    Applicant: ISIS PHARMACEUTICALS INC.
    Inventors: Robert A. Macleod, Youngsoo Kim, Tianyuan Zhou, Susan M. Freier, Punit Seth, Eric Swayze, Brett Monia
  • Patent number: 9187749
    Abstract: Disclosed herein are methods for decreasing Factor 12 and treating or preventing inflammatory conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 12 include hereditary angioedema (HAE). Methods for inhibiting Factor 12 can also be used as a prophylactic treatment to prevent individuals at risk for developing an inflammatory condition, such as, hereditary angioedema.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: November 17, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Gourab Bhattacharjee, Alexey Revenko, Robert A. MacLeod
  • Patent number: 9175291
    Abstract: Certain embodiments are directed to compounds and compositions targeted to human androgen receptor (AR) for inhibiting androgen receptor levels in a cell, which can be useful for methods of treating cancer and inhibiting cancer cell growth or proliferation.
    Type: Grant
    Filed: October 10, 2013
    Date of Patent: November 3, 2015
    Assignee: ISIS Pharmaceuticals Inc.
    Inventors: Robert A. Macleod, Youngsoo Kim, Tianyuan Zhou, Susan M. Freier, Brett Monia
  • Patent number: 9150864
    Abstract: Disclosed herein are methods for decreasing Factor 12 and treating or preventing thromboembolic conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 12 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke, and mesenteric thrombosis. Methods for inhibiting Factor 12 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.
    Type: Grant
    Filed: November 8, 2011
    Date of Patent: October 6, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Robert A. MacLeod, Jeffrey R. Crosby
  • Publication number: 20140371296
    Abstract: The present embodiments provide compounds and methods for reducing expression of Metastasis-Associated-in-Lung-Adenocarcinoma-Transcript-1 (MALAT-1) RNA and/or protein in an animal. Such methods are useful for treating cancer, such as colon cancer, intestinal cancer, lung cancer (e.g. non-small cell lung cancer), liver cancer, and/or prostate cancer. In various aspects, the cancer is a primary cancer.
    Type: Application
    Filed: December 21, 2012
    Publication date: December 18, 2014
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Susan M. Freier, Eric G. Marcusson, Ssucheng J. Hsu, Robert A. MacLeod
  • Publication number: 20140336237
    Abstract: Disclosed herein are antisense compounds and methods for decreasing STAT3 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate hyperproliferative diseases.
    Type: Application
    Filed: July 23, 2014
    Publication date: November 13, 2014
    Inventors: Eric E. Swayze, Susan M. Freier, Robert A. MacLeod, Youngsoo Kim
  • Patent number: 8816056
    Abstract: Disclosed herein are antisense compounds and methods for decreasing STAT3 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate hyperproliferative diseases.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: August 26, 2014
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Eric E. Swayze, Susan M. Freier, Robert A. MacLeod, Youngsoo Kim
  • Publication number: 20140228300
    Abstract: Disclosed herein are methods for decreasing Factor 12 and treating or preventing inflammatory conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 12 include hereditary angioedema (HAE). Methods for inhibiting Factor 12 can also be used as a prophylactic treatment to prevent individuals at risk for developing an inflammatory condition, such as, hereditary angioedema.
    Type: Application
    Filed: June 8, 2012
    Publication date: August 14, 2014
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Gourab Bhattacharjee, Alexey Revenko, Robert A. MacLeod
  • Publication number: 20140213631
    Abstract: Disclosed herein are methods for decreasing kallikrein and treating or preventing inflammatory conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to kallikrein include hereditary angioedema (HAE). Methods for inhibiting kallikrein can also be used as a prophylactic treatment to prevent individuals at risk for developing an inflammatory condition, such as, hereditary angioedema.
    Type: Application
    Filed: June 8, 2012
    Publication date: July 31, 2014
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Gourab Bhattacharjee, Alexey Revenko, Robert A. MacLeod
  • Publication number: 20140206745
    Abstract: Disclosed herein are methods for decreasing kallikrein and treating or preventing thromboembolic conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to kallikrein include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Methods for inhibiting kallikrein can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.
    Type: Application
    Filed: June 29, 2012
    Publication date: July 24, 2014
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Alexey Revenko, Gourab Bhattacharjee, Robert A MacLeod